Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B
Journal of Clinical Virology, 02/28/2012
Kittner JM et al. – The authors observed that the add–on of peg–IFN induced HBsAg seroconversion in 2 out of 12 patients. Response rates may have been higher with prolongation of therapy. The add–on concept merits to be evaluated in a clinical trial.